Manmeet Singh Soni
Known title: Chief Operating OfficerCIK: 0001569769
Manmeet Singh Soni's purchase track record
Manmeet Singh Soni has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/4/2026 | SMMT | $722K | +15.4% | pending | — |
| 10/13/2023 | SMMT | $5.00M | +84.5% | +118.2% | +18.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SMMT | ▲ Buy | Open Market | 25,000 | $362K | 6/4/2026 | View on chart |
| SMMT | ▲ Buy | Open Market | 25,000 | $361K | 6/4/2026 | View on chart |
| SMMT | ▲ Buy | Grant | 53,361 | $1000K | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Grant | 44,052 | $1000K | 9/11/2024 | View on chart |
| SMMT | ▲ Buy | Open Market | 2,976,190 | $5.0M | 10/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo
Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo. Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.